Drug intelligence / Profile preview

carboplatin + cisplatin + osimertinib + pemetrexed

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination chemotherapy regimen consisting of two platinum-based agents (carboplatin and cisplatin), a targeted therapy (osimertinib), and an antifolate chemotherapy drug (pemetrexed). The platinum compounds work by forming DNA cross-links that interfere with cell division, while osimertinib targets EGFR mutations, and pemetrexed inhibits enzymes necessary for purine and pyrimidine synthesis. This combination likely aims to leverage the different toxicity profiles and mechanisms of action of these drugs to enhance efficacy in treating advanced cancers, particularly non-small cell lung cancer.

Brand names: TagrissoAlimtaParaplatinPlatinol
Other names: osimertinibAZD9291AZD-9291AZD 9291pemetrexed disodiumcarboplatincis-diamminedichloroplatinum(II)

Targets

GART (GAR transformylase)EGFR (Epidermal growth factor receptor)DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on carboplatin + cisplatin + osimertinib + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + cisplatin + osimertinib + pemetrexed.

Explore the full profile